A denosine is a ubiquitous molecule with a wide distribution in many tissues and numerous physiological actions in the cardiovascular, nervous, renal, pulmonary, and immune systems. Exposure of rabbit heart to adenosine increases tolerance of the myocardium to subsequent ischemia, 1 similar to ischemic preconditioning. In isolated hearts, adenosine enhanced recovery of contractile function after no-flow ischemia compared with control hearts. 2 The protective role of adenosine against myocardial ischemia/reperfusion injury has also been observed in situ 3 as infarct size is significantly reduced by adenosine infusion during the reperfusion period. The protective role of adenosine in ischemia/reperfusion injury has also been documented in human studies. In a prospective clinical trial, the Acute Myocardial Infarction Study of Adenosine (AMISTAD) trial, adenosine given within 6 hours of the onset of acute myocardial infarction resulted in a significant reduction in infarct size. 4 Although the myocardial protective role of adenosine is widely recognized, the underlying mechanism still remains unclear. Owing to an important role of reactive oxygen species (ROS) in ischemia/ reperfusion injury in myocardium as well as in the brain, 5, 6 it is likely that adenosine may increase resistance to oxidative stress.
In fact, studies in cultured chick cardiomyocytes showed that the adenosine agonist, AMP579, directly protects these cells by attenuating intracellular oxidant stress during reoxygenation. 7 Adenosine attenuates oxidant injury in human proximal tubular cells, 8 and in vivo, adenosine treatment before or after ischemia protects the kidney from ischemia/reperfusion injury. 9, 10 Adenosine also provides protection against oxidant injury in neural cells 11 and plays a role in cerebral ischemic preconditioning. 12 Glutathione peroxidases (GPxs) are selenocysteinecontaining proteins that serve an important role in the cellular defense against oxidant stress by reducing H 2 O 2 and a wide range of organic hydroperoxides. GPx-1, cellular glutathione peroxidase, is the most abundant isoform within eukaryotic cells and is a major intracellular antioxidant enzyme. 13 GPx-1 transcription is induced by oxidant stress, 14 and levels of GPx-1 increase during ischemia/reperfusion. 15, 16 Previously, we have found that GPx-1-deficient mice have endothelial dysfunction, an increase in the oxidant stress products iPF 2␣ -III isoprostanes, and abnormal cardiac function after ischemia/reperfusion injury. 17, 18 Other studies suggest a protective role for GPx-1 in ischemia/reperfusion as increased expres-sion of GPx-1 in transgenic mice decreases tissue damage after cerebral or myocardial ischemia/reperfusion. 19, 20 In this report, we examine the relationship between adenosine and GPx-1 in mediating cytoprotection against oxidant stress.
Materials and Methods

Chemicals and Reagents
Adenosine and EHNA [erytho-9-(2-hydroxy-3-nonyl)adenine] were obtained from Sigma. PD98059, SB203580, bisindolylmaleimide I (BIM), and LY294002 were obtained from Calbiochem. FuGENE 6 transfection reagent was obtained from Roche Molecular Biochemicals. Anti-human GPx-1 monoclonal antibody was purchased from Medical & Biological Laboratories Co, anti-␤-actin antibody was obtained from Santa Cruz Biotechnology, and peroxidase-conjugated anti-mouse and anti-goat antibody were purchased from Sigma.
Cell Culture
Primary human pulmonary artery endothelial cells (HPAECs) were purchased from Cambrex and were used up to passage 10. Cells were grown in endothelial growth medium-2-MV (EGM-2-MV, Cambrex) to 90% to 95% confluence, and then treated with reagents as supplements to endothelial growth medium-2 (EGM-2, Clonetics), as indicated.
Northern Blot Analysis
HPAECs were grown to 90% confluence in EGM-2-MV medium in 60-mm dishes and treated with different reagents in the presence of EGM-2. Total RNA was extracted with Trizol (Invitrogen); 5 g total RNA from each sample was fractionated on 1.2% formaldehyde-agarose gels and transferred onto GeneScreen Plus membranes. Human GPx-1 or glyceraldehyde-3-phosphate dehydrogenase (G3PDH) cDNA fragments were labeled with ␣-[ 32 P]dCTP using a random priming kit (Roche Molecular Biochemicals), and hybridization was performed for 3 hours at 65°C in Quickhyb solution (Strategene), followed by serial washes for 15 minutes each in 0.1X SSC, 0.1% SDS at room temperature, 45°C, and 65°C. Membranes were stripped and rehybridized with the G3PDH probe. The quantitative analysis of hybridization signals was performed using ZeroDscan software or after scanning with a Versadoc imager. Analysis was performed with the QuantityOne software from Biorad. To correct for gel loading, GPx-1 band densities were normalized to G3PDH band densities.
GPX-1 mRNA Stability
HPAECs were grown to 90% confluence in EGM-2-MV and then in EGM-2 medium with or without supplementation with 50 mol/L adenosine /10 mol/L EHNA for 48 hours. Actinomycin D at a concentration of 5 g/mL was then added, and cells were harvested at 2, 4, 6, 9.5, and 11 hours. Total RNA was subjected to Northern blot analysis for GPx-1 expression.
GPx-1 Promoter Activity Analysis
A human GPx-1 promoter fragment (Ϫ580/ϩ47) cloned into the pGL-3 basic vector (Promega) was used to assay promoter function. HPAECs were seeded into 12 well plates at a density of 5ϫ10 4 /mL in EGM-2-MV medium. The human GPx-1 promoter construct (0.5 g) was mixed with 3 L of FuGENE 6 and 25 ng renilla luciferase control reporter vector, pRL-CMV (Promega), for each well, and incubated with the cells for 6 hours. Medium was then replaced with fresh EGM-2 medium supplemented with various reagents. After 24 hours, cells were lysed, and the luciferase and renilla luciferase activities were measured with a luminometer (Turner Designs, TD-20e). Luciferase activity was corrected with renilla luciferase activity to normalize for transfection efficiency.
Western Blot Analysis of GPx-1
For determination of GPx-1 protein expression levels, HPAECs were lysed with ice-cold RIPA buffer (50 mmol/L Tris-HCl, pH 7.4, 150 mmol/L NaCl, 1% NP40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate) supplemented with a protease inhibitor cocktail (Pierce Biotechnology). Protein samples (30 g) were separated on 10% SDS-polyacrylamide gels (BioRad) and transferred to nitrocellulose membranes. The membranes were probed with 10 g/mL monoclonal anti-GPx-1 antibody, followed by a 1:2000 dilution of peroxidase-conjugated anti-mouse IgG antibody (Sigma). Detection was accomplished with an ECL reagent (Amersham). The membranes were then stripped and reprobed with 1 g/mL anti-␤-actin antibody.
Cellular GPx Activity Assay
HPAECs were grown on 100-mm dishes until 80% confluent. Cells were treated with reagents dissolved in EGM-2 for 2 days, with fresh medium and reagents added daily. Cellular extracts were prepared by sonication in ice-cold buffer (50 mmol/L Tris-HCl, pH 7.5, 5 mmol/L EDTA, and 1 mmol/L DTT). After sonication, lysed cells were centrifuged at 10 000g for 20 minutes, and GPx-1 activity was measured in the supernatant. Cellular GPx activity (nmol NADPH/ min/mL) was measured using an assay kit (Calbiochem) that measures the coupled oxidation of NADPH during glutathione reductase (GR) recycling of oxidized glutathione from GPx-1-mediated reduction of t-butyl peroxide. In the assay, excess GR, glutathione, and NADPH were added. The activity was normalized to protein concentration.
Trypan Blue Exclusion
HPAECs were treated with or without 50 mol/L adenosine/ 10 mol/L EHNA for 48 hours. Cells were then transferred into 100-mm plates for an additional 4 hours of treatment with adenosine/EHNA and/or 10 mmol/L mercaptosuccinate (MSA), an inhibitor of GPx-1. After removal of this media, cells were then treated with 500 mol/L H 2 O 2 for 2 hours, after which they were trypsinized and prepared for trypan blue exclusion. Briefly, cells were resuspended in HBSS buffer (Cambrex), mixed 1:1 with 0.4% trypan blue (Sigma), and incubated for 5 minutes, after which stained and unstained cells were counted separately with a hemocytometer. Cells stained blue were considered nonviable, whereas unstained cells were considered viable. The percentage of stained cells was used as an index of cell death. 
Transfection With siRNA
Results
Adenosine/EHNA Induces GPx-1 Expression
To determine the effects of adenosine on GPx-1 expression, HPAECs were treated with 50 mol/L adenosine and 10 mol/L EHNA, or pretreated with 10 mol/L EHNA for 30 minutes followed by adenosine for 48 hours. Fresh media and reagents were replaced every 24 hours. Adenosine or EHNA alone did not significantly affect GPx-1 mRNA; however, in the presence of EHNA, adenosine significantly induced GPx-1 mRNA expression (PϽ0.02) ( Figure 1A ). The induction of GPx-1 mRNA was dose-dependent (PϽ0.05) ( Figure 1B) . Additional experiments showed that this effect could not be detected earlier than 24 hours following the initiation of treatment (data not shown).
To assess whether increases in GPx-1 mRNA corresponded to increases in GPx-1 protein expression and enzyme activity, the combination of adenosine/EHNA was used to treat cells for 48 hours, after which cellular extracts were analyzed for GPx-1 protein and for GPx-1 enzyme activity. Western blot analysis showed that adenosine/EHNA increased GPx-1 protein levels 2.3Ϯ0.3-fold (PϽ0.05) ( Figure   2A ), under conditions where mRNA levels increased Ϸ2-fold (PϽ0.02) ( Figure 1A ). There was no effect of EHNA or adenosine alone on GPx-1 protein expression (data not shown). Cellular GPx-1 activity was also increased 2.2Ϯ0.2-fold (PϽ0.05) ( Figure 2B ) with adenosine/EHNA treatment. Similar results were also observed in human coronary artery endothelial cells (data not shown).
Adenosine/EHNA Decreases GPx-1 mRNA Degradation
To determine the mechanism by which adenosine/EHNA upregulates GPx-1 mRNA, the human GPx-1 promoter construct was transfected into HPAECs. After 24-hour treatment with adenosine, EHNA, or adenosine/EHNA, luciferase activity was measured ( Figure 3A) . Adenosine alone had no significant effect on luciferase activity. EHNA caused a small (18%) but significant (PϽ0.05) increase in luciferase activity. By contrast, adenosine/EHNA decreased the activity of the GPx-1 promoter by Ϸ35% (PϽ0.005), indicating that the upregulation of mRNA levels is a not a result of enhanced GPx-1 gene transcription. In the presence of actinomycin D, GPx-1 mRNA levels decreased by almost 50% after 11 hours of treatment ( Figure 3B ). Pretreatment with adenosine/EHNA increased GPx-1 mRNA stability such that no change in GPx-1 mRNA was detected in this time frame. Longer treatments with actinomycin D appeared to cause cell death. These data suggest that adenosine/EHNA increased expression of GPx-1 by increasing GPx-1 mRNA stability and not by increasing GPx-1 gene transcription.
Signaling Pathways Mediating the Adenosine/EHNA-Dependent Induction of GPx-1
To study the signaling pathway involved in the induction of GPx-1 by adenosine, we performed Northern blot analysis of GPx-1 mRNA from nontreated and adenosine/EHNAtreated HPAECs in the presence or absence of inhibitors of mitogen-activated protein kinase (MAPK), protein kinase C (PKC), and phosphatidylinositol 3-kinase (PI3K) (Figure 4 ). Northern blot analysis showed that pretreatment with the PKC inhibitor BIM blocked GPx-1 induction by adenosine by Ϸ36% (PϽ0.05), whereas the MAPK inhibitor SB203580 augmented GPx-1 induction by 38% (PϽ0.05). These results indicate that adenosine-mediated GPx-1 induction is partially mediated by PKCdependent pathways and suggest that MAPK pathways may suppress GPx-1 expression.
Adenosine/EHNA Treatment Protects HPAECs From H 2 O 2 -Induced Cell Death
To determine whether the increase in GPx-1 expression resulted in an increase in intracellular antioxidant capacity, adenosine/ EHNA-treated and untreated cells were challenged with 500 mol/L H 2 O 2 for 2 hours and assayed for cell death by trypan blue exclusion ( Figure 5 ). Cells not treated with adenosine/EHNA and exposed to H 2 O 2 ( Figure 5A and 5B) showed a significant, Ϸ2-fold increase in cell death (PϽ0.05). By contrast, cells treated with adenosine/EHNA and exposed to H 2 O 2 showed only a small, nonsignificant increase in cell death ( Figure 5A and 5B). These data suggest that adenosine/EHNA treatment can improve the antioxidant capacity of endothelial cells. Pretreatment of cells with MSA, a GPx-1 inhibitor, led to an Ϸ5-fold increase in cell death in both untreated cells and cells treated with adenosine/EHNA, abolishing the protective effects of adenosine/EHNA treatment. To confirm that GPx-1 levels contribute to cellular protection against oxidants, siRNA was used to knockdown the expression of the enzyme, followed by adenosine/EHNA treatment and H 2 O 2 exposure. siRNA transfection significantly increased cell death in response to H 2 O 2 treatment (PϽ0.0005), whereas adenosine/EHNA cells transfected with the control (scrambled) 310 siRNA showed no significant increase in cell death in response to H 2 O 2 treatment. Importantly, the level of cell death in the siRNA transfection after treatment with H 2 O 2 is significantly greater than that measured in the control transfection treated with H 2 O 2 (PϽ0.02).
Discussion
In this study, we found that adenosine/EHNA can upregulate GPx-1 expression and activity by decreasing GPx-1 mRNA degradation in endothelial cells. Adenosine is released in small amounts at a constant basal rate during normoxia in myocardium. During ischemia, the release of adenosine can increase 50-fold, 21 and, therefore, endogenously generated adenosine released during acute myocardial ischemia is likely sufficient to induce GPx-1 expression.
Ischemic preconditioning has two phases, an early phase and a delayed phase. The early phase involves receptormediated signaling events that include the opening of potassium channels, the activation of kinases, and, in endothelial cells, the activation of vasodilatory responses. 22 It has been speculated that the delayed phase of preconditioning involves de novo synthesis of cardioprotective proteins and posttranslational protein modification. 23 The data presented in this study show that adenosine upregulates GPx-1 mRNA levels and that GPx-1 enzyme activity increases in parallel. This upregulation is the result of adenosine's prolonging the half-life of the GPx-1 mRNA rather than facilitating gene transcription; the relatively long half-life of GPx-1 mRNA accounts for the response to adenosine requiring 24 hours of treatment.
GPx-1 expression and activity are enhanced by ROS 14 and hyperoxia, 24 and reduced by selenium depletion 25 and TGF-␤. 26 The effects of ROS and hyperoxia have been shown to be transcriptional, whereas selenium alters mRNA stability and translation of this selenocysteine-containing protein. The unique mechanism of selenocysteine incorporation at a UGA codon involves several translational cofactors, including proteins that bind to the GPx-1 mRNA and stabilize interactions among the mRNA, a specific selenocysteine elongation factor, and a selenocysteine tRNA at the ribosome. 13, 27 The presence of selenium appears to prevent nonsense-mediated decay of the GPx-1 mRNA. 28 Inhibition of translation by puromycin, which disrupts polyribosome formation, leads to a decrease in the half-life of GPx-1 mRNA. 29 Thus, there are multiple lines of evidence for a relationship between efficient translation and stability of the GPx-1 mRNA.
BIM-1 treatment partially blocks the adenosine-mediated increase in GPx-1 mRNA. This pharmacological inhibitor was used because it is most effective in targeting all PKCsubtypes; however, it has also been found to interfere with the activity of glycogen synthase kinase. 30 Adenosine-mediated signaling is known to result in PKC-activation in many different cell types including endothelial cells; therefore, in our cell system it is most likely that the adenosine-mediated increase in GPx-1 mRNA that is sensitive to BIM 1 treatment is mediated by PKC.
RNA turnover, in some transcripts, is influenced by specific protein binding to AU-rich elements in the 3Ј untranslated region (UTR) of the mRNA followed by subsequent deadenylation and exonuclease degradation. 31 Additional RNA binding factors, such as the hnRNP factors, which recognize UCCCA motifs, and nucleolin, which recognizes U/G CCCG A/G motifs, can stabilize mRNA. 32, 33 We analyzed the sequence of the 3Ј UTR of the GPx-1 mRNA for these motifs and identified one site for nucleolin binding. Published reports have shown that nucleolin can bind to the GPx-1 3Ј UTR, 34 and others have reported that nucleolin can be targeted by some PKC isoforms. 35 Additional studies are necessary to determine the precise role of PKC, and nucleolin in GPx-1 expression.
Other factors may influence the expression and activity of GPx-1. Recent analysis has suggested that nitric oxide (NO) can posttranslationally modify selenocysteine, thereby inactivating GPx-1; however, this effect requires high levels of NO generated from NO-donors or LPS-activation of iNOS. 36, 37 Treatments with inhibitors, such as L-buthionine sulfoximine, that decrease glutathione (GSH) production also decrease GPx-1-mediated protection against oxidative stress. 38 -40 Similarly, treatment with GSH precursors, such as N-acetylcysteine or L-2-oxothiazolidine-4-carboxylic acid, result in an increase in GSH production and augment GPx-1-mediated protection. 39, 41 Theoretically, oxidation of GSH to GSSG would also decrease GPx-1 activity. Increased GSSG levels have been measured after oxidant stress; however, these changes reflect GSH oxidation by GPx-1. 42, 43 Levels of reduced GSH are restored and kept virtually unchanged under most cellular conditions by the adaptive responses of glutathione reductase and other enzymes involved in GSH biosynthesis. 44 Importantly, in our studies, the increase in mRNA stability correlated with an increase in GPx-1 protein levels and a significant increase in GPx-1 enzyme activity. It is most likely that the increase in enzyme activity in this system is solely a result of an increase in protein levels as the magnitude of these changes are similar. Concurrent with the increase in GPx-1 levels and activity, there was an increase in protection against H 2 O 2 -induced cell damage. MSA, a pharmacological inhibitor of GPx-1, blocked protective effects of adenosine/EHNA treatment on endothelial cells; however, MSA may have other effects on the cells. Importantly, specific targeting of GPx-1 with siRNA that resulted in decreased levels of GPx-1 protein also abrogated the protective effects of adenosine/EHNA treatment on endothelial cells.
In endothelial cells, hydrogen peroxide detoxification is primarily mediated by GPx-1 as catalase is reportedly not expressed or expressed at very low levels in these cells. 45, 46 Our cell culture studies showed that decreasing the levels of GPx-1 increases sensitivity to oxidants, whereas increasing levels of GPx-1 decreases sensitivity to oxidants. These findings are in agreement with other cell culture studies that used transfection methods to overexpress GPx-1, resulting in a protection against oxidative stress. 47, 48 In vivo studies have found that a reduction of GPx-1 expression by Ϸ50%, as in heterozygous murine knockout of GPx-1, is sufficient to cause endothelial dysfunction and oxidative stress. 17 Other studies in transgenic and overexpressing mice illustrate the importance of GPx-1 expression to protect against oxidant injury during ischemia/reperfusion or direct oxidant exposure. For example, GPx-1 null mice showed increased infarct size and augmented neuronal sensitivity to apoptosis in a cerebral ischemia/reperfusion model, 49 whereas GPx-1 overexpression protected against ischemia/reperfusion injury. 19 Similarly, GPx-1-deficient mice have impaired cardiac function after ischemia/reperfusion injury 17 and an increased susceptibility to oxidants, such as paraquat and H 2 O 2 , 14 whereas GPx-1 overexpression protected against myocardial ischemia/ reperfusion injury. 20 In this current study, the novel finding is that adenosine can mediate increased expression of this antioxidant enzyme, which results in enhanced cellular tolerance to H 2 O 2 . Thus, we speculate that augmented activity of GPx-1 may contribute to the cardioprotective role of adenosine in cardiac ischemia/reperfusion and preconditioning, especially late preconditioning, by increasing cellular tolerance to oxidant stress.
Extracellular adenosine mediates physiological responses via activation of G-protein-coupled adenosine receptors, or it is transported into the cells via nucleoside transporters where it is metabolized by adenosine deaminase or adenosine kinase. Adenosine deaminase is the major enzyme that catabolizes this nucleoside. 50 Previous studies have shown that adenosine receptors are rapidly desensitized after continued adenosine treatment. In our study, adenosine was replenished in the media daily, and EHNA, an adenosine deaminase inhibitor, was included to increase the half-life of adenosine.
Many studies demonstrate that adenosine has a protective role against ischemia/reperfusion injury and can promote preconditioning for subsequent ischemia. In cultured cells, adenosine was found to activate the cellular antioxidant defense system by enhancing the activities of several antioxidant enzymes, including GPx-1 51 ; however, unlike our results, this effect was detected within 1 hour. This study also differs from our study in that cells were first treated with adenosine deaminase to remove endogenous levels of adenosine: this pretreatment actually significantly lowered the levels of the antioxidant enzymes including GPx-1. A single dose of an A 1 -selective adenosine receptor agonist 24 hours before coronary artery occlusion in rabbits led to protection from ischemic injury, suggesting a delayed, but long-acting, effect of adenosine receptor activation. 52 It appears that adenosine enhances GPx-1 expression partially though a PKC-dependent mechanism. By use of specific receptor agonists, both the A 1 and A 3 subtypes have been associated with protective preconditioning in the myocardium, 53 whereas A 2A receptors have been shown to promote the vasodilatory effects of endothelial cells. 22 It has been established that PKC is an obligatory mediator of delayed ischemic preconditioning, 54, 55 and A 1 , A 3 , and A 2A have all been associated with mediating cytoprotection via PKC-dependent pathways. Owing to the timeframe for the upregulation of GPx-1 expression and the ability of the PKC inhibitor to block this increase, our findings suggest that adenosine-mediated increases in GPx-1 levels may play a role in delayed or late-phase ischemic preconditioning.
